A comparative study on the efficacy and the safety of cefuroxime and cefazolin in respiratory tract infections by doubie blind method

Keiichi Nakagawa; Tatsuo Suzuki; Kentaro Watanabe; Toshio Kihara; Kazuo Kurizuka; Hirosuke Nakazawa; Masato Sogo; Yasuichi Kato; Akira Saito; Kiyobumi Ishikawa; Ichiro Nakayama; Masumi Tomizawa; Takanori Sakuraba; Yoshio Kinoshita; Kazuo Takebe; Kenichi Imamura; Yoshihiro Kumazaka; Osamu Uehara; Mitsuo Masuda; Yuzuru Fujioka; Hiroshi Saito; Yasuhisa Abe; Tsuneharu Baba; Tetsuo Komori; Ichiro Hirai; Shiro Kosaka; Shuichiro Yoshida; Akira Watanabe; Seiichi Aonuma; Kikuo Onuma; Masako Sasaki; Kotaro Oizumi; Kiyoshi Konno; Izumi Hayashi; Shigeru Tamaki; Masataka Katsu; Shinji Okui; Mieko Kawai; Masanori Adachi; Takashi Soma; Yasushi Ueda; Atsushi Saito; Kazufuto Fukaya; Otohiko Kunii; Junzaburo Kabe; Tetsuzo Watanabe; Yoshito Saito; Ippei Fujimori; Tetsuji Katayama; Fuyuhiko Higashi; Michinori Kono; Kokichi Fukushima; Akira Ito; Kunihiko Shindo; Hiroshi Yamaguchi; Ryuichiro Yamazaki; Takashi Suyama; Makio Kurihara; Hideyuki Hasegawa; Takahito Goto; Hajimu Takeda; Yasutami Kinoshita; Yo Tanaka; Shiro Kawashima; Masanaga Takato; Fusanosuke Yamasaku; Yasutoshi Suzuki; Osamu Skine; Yoshimaru Usuda; Nobuki Aoki; Kaoru Oyama; Michiko Kanaki; Kunio Suzuki; Saburo Kitaura; Kunio Nanjo; Joichi Kato; Toshiyuki Yamamoto; Kenzo Shiota; Fumio Miki; Masakazu Kono; Hiroshi Okubo; Yuruko Okamoto; Yoshiro Ueda; Keigo Maehara; Takehiro Tsujimoto; Kenichi Shimizu; Hiroshi Maruyama; Rinzo Soejima; Yoshihiko Tano; Yoshihito Niki; Osamu Kurimura; Kazue Tamaki; Hideo Sasaki; Kohei Hara; Masao Nakatomi; Atsushi Saito; Masaru Nasu; Kinichi Jzumikawa; Hiromaro Iwasaki; Akira Ikebe; Tsuneo Tsutsumi; Rokushi Oka; Mitsunobu Akaishi; Akimitsu Tomonaga; Keizo Matsumoto; Harumi Shishido; Masatoshi Ide; Haruhiko Tokuomi; Kiyoshi Shima; Yasutsugu Fukuda; Kazuhiro Hamada; Katsumasa Tokunaga; Yoshio Takaba; Kazuo Ishizaka; Yasumasa Hiro; Noritaka Tateishi; Isaoshi Mishima; Ryuji Kaku; Sadanobu Higuchi; Norihiko Nakahara; Tatsuo Tomita; Genshin Takeuchi; Akio Oba; Haruo Nozute

doi:10.11250/chemotherapy1953.28.687

A comparative study on the efficacy and the safety of cefuroxime and cefazolin in respiratory tract infections by doubie blind method

Keiichi Nakagawa, Tatsuo Suzuki, Kentaro Watanabe, Toshio Kihara, Kazuo Kurizuka, Hirosuke Nakazawa, Masato Sogo, Yasuichi Kato, Akira Saito, Kiyobumi Ishikawa, Ichiro Nakayama, Masumi Tomizawa, Takanori Sakuraba, Yoshio Kinoshita, Kazuo Takebe, Kenichi Imamura, Yoshihiro Kumazaka, Osamu Uehara, Mitsuo Masuda, Yuzuru FujiokaHiroshi Saito, Yasuhisa Abe, Tsuneharu Baba, Tetsuo Komori, Ichiro Hirai, Shiro Kosaka, Shuichiro Yoshida, Akira Watanabe, Seiichi Aonuma, Kikuo Onuma, Masako Sasaki, Kotaro Oizumi, Kiyoshi Konno, Izumi Hayashi, Shigeru Tamaki, Masataka Katsu, Shinji Okui, Mieko Kawai, Masanori Adachi, Takashi Soma, Yasushi Ueda, Atsushi Saito, Kazufuto Fukaya, Otohiko Kunii, Junzaburo Kabe, Tetsuzo Watanabe, Yoshito Saito, Ippei Fujimori, Tetsuji Katayama, Fuyuhiko Higashi, Michinori Kono, Kokichi Fukushima, Akira Ito, Kunihiko Shindo, Hiroshi Yamaguchi, Ryuichiro Yamazaki, Takashi Suyama, Makio Kurihara, Hideyuki Hasegawa, Takahito Goto, Hajimu Takeda, Yasutami Kinoshita, Yo Tanaka, Shiro Kawashima, Masanaga Takato, Fusanosuke Yamasaku, Yasutoshi Suzuki, Osamu Skine, Yoshimaru Usuda, Nobuki Aoki, Kaoru Oyama, Michiko Kanaki, Kunio Suzuki, Saburo Kitaura, Kunio Nanjo, Joichi Kato, Toshiyuki Yamamoto, Kenzo Shiota, Fumio Miki, Masakazu Kono, Hiroshi Okubo, Yuruko Okamoto, Yoshiro Ueda, Keigo Maehara, Takehiro Tsujimoto, Kenichi Shimizu, Hiroshi Maruyama, Rinzo Soejima, Yoshihiko Tano, Yoshihito Niki, Osamu Kurimura, Kazue Tamaki, Hideo Sasaki, Kohei Hara, Masao Nakatomi, Atsushi Saito, Masaru Nasu, Kinichi Jzumikawa, Hiromaro Iwasaki, Akira Ikebe, Tsuneo Tsutsumi, Rokushi Oka, Mitsunobu Akaishi, Akimitsu Tomonaga, Keizo Matsumoto, Harumi Shishido, Masatoshi Ide, Haruhiko Tokuomi, Kiyoshi Shima, Yasutsugu Fukuda, Kazuhiro Hamada, Katsumasa Tokunaga, Yoshio Takaba, Kazuo Ishizaka, Yasumasa Hiro, Noritaka Tateishi, Isaoshi Mishima, Ryuji Kaku, Sadanobu Higuchi, Norihiko Nakahara, Tatsuo Tomita, Genshin Takeuchi, Akio Oba, Haruo Nozute

Research output: Contribution to journal › Article › peer-review

Abstract

A comparative study of Cefuroxime with Cefazolin for bacterial pneumonia and chronic respiratory tract infections was carried out by the double blind method. Each one of the antibiotics was given in doses of 750 mg I. V. three times daily for seven to fourteen days. 1 Cases subject to analysis: Of 201 cases recruited in this trial, 149 (Cefuroxime 72, Cefazolin 77) were adopted by Committee in evaluation on clinical efficacy and 197 (Cefuroxime 96, Cefazolin 101) were adopted by Controller after judged by doctors in charge. The background characteristics of the patients in Cefuroxime and Cefazolin treated groups were almost the same. 2. Overall clinical efficacy judged by Committee: Cefuroxime was significantly superior to Cefazolin in judgement on the 7 th day of treatment in the “excellent” rate of total cases and of moderate cases, and in the efficacy of cases with infection due to gram positive cocci, etc. Cefuroxime showed also a tendency to be superior to Cefazolin in the “excellent” rate of patients with pneumonia, the efficacy rate of moderate cases and in the clinical efficacy in chronic respiratory tract infections, etc. 3. Overall clinical efficacy judged by doctors in charge: As for the overall clinical efficacy in total cases, there was no significant difference between Cefuroixme and Cefazolin in both judgements on the 7 th day of treatment and at the end of treatment. 4. Improvement of clinical findings: As for the degree of improvement in chest X-ray findings on the 14 th day of treatment compared with the initial ones, Cefuroxime was significantly superior to Cefazolin in cases adopted by Committee and showed a tendency to be superior to Cefazolin in cases adopted by Controller. Besides, Cefazolin showed a tendency to be better than Cefuroxime in property and volume (only cases adopted by Committee) of sputum in the judgement after three days treatment. 5. Bacteriological response classified by clinical isolates from sputum: Cefuroxime showed a tendency to eradicate Heamophilus at a higher rate than Cefazolin. 6. Side effects and abnormal laboratory findings due to the medication: As for the incidence of side effects including abnormal laboratory findings, there was no significant difference between Cefuroxime and Cefazolin in both judgements by Committee (186 cases) and those by doctors in charge (197 cases). 7. Clinical usefulness judged by doctors in charge: Cefuroxime showed a tendency to be superior to Cefazolin in usefulness rate (judged as useful or slightly useful). From the results obtained, it has been concluded that Cefuroxime is a useful antibiotic for treatment of bacterial pneumonia and chronic respiratory tract infections.

Original language	English
Pages (from-to)	687-714
Number of pages	28
Journal	Chemotherapy
Volume	28
Issue number	5
DOIs	https://doi.org/10.11250/chemotherapy1953.28.687
Publication status	Published - 1980
Externally published	Yes

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.28.687

Cite this

Nakagawa, K., Suzuki, T., Watanabe, K., Kihara, T., Kurizuka, K., Nakazawa, H., Sogo, M., Kato, Y., Saito, A., Ishikawa, K., Nakayama, I., Tomizawa, M., Sakuraba, T., Kinoshita, Y., Takebe, K., Imamura, K., Kumazaka, Y., Uehara, O., Masuda, M., ... Nozute, H. (1980). A comparative study on the efficacy and the safety of cefuroxime and cefazolin in respiratory tract infections by doubie blind method. Chemotherapy, 28(5), 687-714. https://doi.org/10.11250/chemotherapy1953.28.687

Nakagawa, K, Suzuki, T, Watanabe, K, Kihara, T, Kurizuka, K, Nakazawa, H, Sogo, M, Kato, Y, Saito, A, Ishikawa, K, Nakayama, I, Tomizawa, M, Sakuraba, T, Kinoshita, Y, Takebe, K, Imamura, K, Kumazaka, Y, Uehara, O, Masuda, M, Fujioka, Y, Saito, H, Abe, Y, Baba, T, Komori, T, Hirai, I, Kosaka, S, Yoshida, S, Watanabe, A, Aonuma, S, Onuma, K, Sasaki, M, Oizumi, K, Konno, K, Hayashi, I, Tamaki, S, Katsu, M, Okui, S, Kawai, M, Adachi, M, Soma, T, Ueda, Y, Saito, A, Fukaya, K, Kunii, O, Kabe, J, Watanabe, T, Saito, Y, Fujimori, I, Katayama, T, Higashi, F, Kono, M, Fukushima, K, Ito, A, Shindo, K, Yamaguchi, H, Yamazaki, R, Suyama, T, Kurihara, M, Hasegawa, H, Goto, T, Takeda, H, Kinoshita, Y, Tanaka, Y, Kawashima, S, Takato, M, Yamasaku, F, Suzuki, Y, Skine, O, Usuda, Y, Aoki, N, Oyama, K, Kanaki, M, Suzuki, K, Kitaura, S, Nanjo, K, Kato, J, Yamamoto, T, Shiota, K, Miki, F, Kono, M, Okubo, H, Okamoto, Y, Ueda, Y, Maehara, K, Tsujimoto, T, Shimizu, K, Maruyama, H, Soejima, R, Tano, Y, Niki, Y, Kurimura, O, Tamaki, K, Sasaki, H, Hara, K, Nakatomi, M, Saito, A, Nasu, M, Jzumikawa, K, Iwasaki, H, Ikebe, A, Tsutsumi, T, Oka, R, Akaishi, M, Tomonaga, A, Matsumoto, K, Shishido, H, Ide, M, Tokuomi, H, Shima, K, Fukuda, Y, Hamada, K, Tokunaga, K, Takaba, Y, Ishizaka, K, Hiro, Y, Tateishi, N, Mishima, I, Kaku, R, Higuchi, S, Nakahara, N, Tomita, T, Takeuchi, G, Oba, A & Nozute, H 1980, 'A comparative study on the efficacy and the safety of cefuroxime and cefazolin in respiratory tract infections by doubie blind method', Chemotherapy, vol. 28, no. 5, pp. 687-714. https://doi.org/10.11250/chemotherapy1953.28.687

@article{00f2c25b0e87435aa6bf828a83279a1d,

title = "A comparative study on the efficacy and the safety of cefuroxime and cefazolin in respiratory tract infections by doubie blind method",

abstract = "A comparative study of Cefuroxime with Cefazolin for bacterial pneumonia and chronic respiratory tract infections was carried out by the double blind method. Each one of the antibiotics was given in doses of 750 mg I. V. three times daily for seven to fourteen days. 1 Cases subject to analysis: Of 201 cases recruited in this trial, 149 (Cefuroxime 72, Cefazolin 77) were adopted by Committee in evaluation on clinical efficacy and 197 (Cefuroxime 96, Cefazolin 101) were adopted by Controller after judged by doctors in charge. The background characteristics of the patients in Cefuroxime and Cefazolin treated groups were almost the same. 2. Overall clinical efficacy judged by Committee: Cefuroxime was significantly superior to Cefazolin in judgement on the 7 th day of treatment in the “excellent” rate of total cases and of moderate cases, and in the efficacy of cases with infection due to gram positive cocci, etc. Cefuroxime showed also a tendency to be superior to Cefazolin in the “excellent” rate of patients with pneumonia, the efficacy rate of moderate cases and in the clinical efficacy in chronic respiratory tract infections, etc. 3. Overall clinical efficacy judged by doctors in charge: As for the overall clinical efficacy in total cases, there was no significant difference between Cefuroixme and Cefazolin in both judgements on the 7 th day of treatment and at the end of treatment. 4. Improvement of clinical findings: As for the degree of improvement in chest X-ray findings on the 14 th day of treatment compared with the initial ones, Cefuroxime was significantly superior to Cefazolin in cases adopted by Committee and showed a tendency to be superior to Cefazolin in cases adopted by Controller. Besides, Cefazolin showed a tendency to be better than Cefuroxime in property and volume (only cases adopted by Committee) of sputum in the judgement after three days treatment. 5. Bacteriological response classified by clinical isolates from sputum: Cefuroxime showed a tendency to eradicate Heamophilus at a higher rate than Cefazolin. 6. Side effects and abnormal laboratory findings due to the medication: As for the incidence of side effects including abnormal laboratory findings, there was no significant difference between Cefuroxime and Cefazolin in both judgements by Committee (186 cases) and those by doctors in charge (197 cases). 7. Clinical usefulness judged by doctors in charge: Cefuroxime showed a tendency to be superior to Cefazolin in usefulness rate (judged as useful or slightly useful). From the results obtained, it has been concluded that Cefuroxime is a useful antibiotic for treatment of bacterial pneumonia and chronic respiratory tract infections.",

author = "Keiichi Nakagawa and Tatsuo Suzuki and Kentaro Watanabe and Toshio Kihara and Kazuo Kurizuka and Hirosuke Nakazawa and Masato Sogo and Yasuichi Kato and Akira Saito and Kiyobumi Ishikawa and Ichiro Nakayama and Masumi Tomizawa and Takanori Sakuraba and Yoshio Kinoshita and Kazuo Takebe and Kenichi Imamura and Yoshihiro Kumazaka and Osamu Uehara and Mitsuo Masuda and Yuzuru Fujioka and Hiroshi Saito and Yasuhisa Abe and Tsuneharu Baba and Tetsuo Komori and Ichiro Hirai and Shiro Kosaka and Shuichiro Yoshida and Akira Watanabe and Seiichi Aonuma and Kikuo Onuma and Masako Sasaki and Kotaro Oizumi and Kiyoshi Konno and Izumi Hayashi and Shigeru Tamaki and Masataka Katsu and Shinji Okui and Mieko Kawai and Masanori Adachi and Takashi Soma and Yasushi Ueda and Atsushi Saito and Kazufuto Fukaya and Otohiko Kunii and Junzaburo Kabe and Tetsuzo Watanabe and Yoshito Saito and Ippei Fujimori and Tetsuji Katayama and Fuyuhiko Higashi and Michinori Kono and Kokichi Fukushima and Akira Ito and Kunihiko Shindo and Hiroshi Yamaguchi and Ryuichiro Yamazaki and Takashi Suyama and Makio Kurihara and Hideyuki Hasegawa and Takahito Goto and Hajimu Takeda and Yasutami Kinoshita and Yo Tanaka and Shiro Kawashima and Masanaga Takato and Fusanosuke Yamasaku and Yasutoshi Suzuki and Osamu Skine and Yoshimaru Usuda and Nobuki Aoki and Kaoru Oyama and Michiko Kanaki and Kunio Suzuki and Saburo Kitaura and Kunio Nanjo and Joichi Kato and Toshiyuki Yamamoto and Kenzo Shiota and Fumio Miki and Masakazu Kono and Hiroshi Okubo and Yuruko Okamoto and Yoshiro Ueda and Keigo Maehara and Takehiro Tsujimoto and Kenichi Shimizu and Hiroshi Maruyama and Rinzo Soejima and Yoshihiko Tano and Yoshihito Niki and Osamu Kurimura and Kazue Tamaki and Hideo Sasaki and Kohei Hara and Masao Nakatomi and Atsushi Saito and Masaru Nasu and Kinichi Jzumikawa and Hiromaro Iwasaki and Akira Ikebe and Tsuneo Tsutsumi and Rokushi Oka and Mitsunobu Akaishi and Akimitsu Tomonaga and Keizo Matsumoto and Harumi Shishido and Masatoshi Ide and Haruhiko Tokuomi and Kiyoshi Shima and Yasutsugu Fukuda and Kazuhiro Hamada and Katsumasa Tokunaga and Yoshio Takaba and Kazuo Ishizaka and Yasumasa Hiro and Noritaka Tateishi and Isaoshi Mishima and Ryuji Kaku and Sadanobu Higuchi and Norihiko Nakahara and Tatsuo Tomita and Genshin Takeuchi and Akio Oba and Haruo Nozute",

year = "1980",

doi = "10.11250/chemotherapy1953.28.687",

language = "English",

volume = "28",

pages = "687--714",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "5",

}

TY - JOUR

T1 - A comparative study on the efficacy and the safety of cefuroxime and cefazolin in respiratory tract infections by doubie blind method

AU - Nakagawa, Keiichi

AU - Suzuki, Tatsuo

AU - Watanabe, Kentaro

AU - Kihara, Toshio

AU - Kurizuka, Kazuo

AU - Nakazawa, Hirosuke

AU - Sogo, Masato

AU - Kato, Yasuichi

AU - Saito, Akira

AU - Ishikawa, Kiyobumi

AU - Nakayama, Ichiro

AU - Tomizawa, Masumi

AU - Sakuraba, Takanori

AU - Kinoshita, Yoshio

AU - Takebe, Kazuo

AU - Imamura, Kenichi

AU - Kumazaka, Yoshihiro

AU - Uehara, Osamu

AU - Masuda, Mitsuo

AU - Fujioka, Yuzuru

AU - Saito, Hiroshi

AU - Abe, Yasuhisa

AU - Baba, Tsuneharu

AU - Komori, Tetsuo

AU - Hirai, Ichiro

AU - Kosaka, Shiro

AU - Yoshida, Shuichiro

AU - Watanabe, Akira

AU - Aonuma, Seiichi

AU - Onuma, Kikuo

AU - Sasaki, Masako

AU - Oizumi, Kotaro

AU - Konno, Kiyoshi

AU - Hayashi, Izumi

AU - Tamaki, Shigeru

AU - Katsu, Masataka

AU - Okui, Shinji

AU - Kawai, Mieko

AU - Adachi, Masanori

AU - Soma, Takashi

AU - Ueda, Yasushi

AU - Saito, Atsushi

AU - Fukaya, Kazufuto

AU - Kunii, Otohiko

AU - Kabe, Junzaburo

AU - Watanabe, Tetsuzo

AU - Saito, Yoshito

AU - Fujimori, Ippei

AU - Katayama, Tetsuji

AU - Higashi, Fuyuhiko

AU - Kono, Michinori

AU - Fukushima, Kokichi

AU - Ito, Akira

AU - Shindo, Kunihiko

AU - Yamaguchi, Hiroshi

AU - Yamazaki, Ryuichiro

AU - Suyama, Takashi

AU - Kurihara, Makio

AU - Hasegawa, Hideyuki

AU - Goto, Takahito

AU - Takeda, Hajimu

AU - Kinoshita, Yasutami

AU - Tanaka, Yo

AU - Kawashima, Shiro

AU - Takato, Masanaga

AU - Yamasaku, Fusanosuke

AU - Suzuki, Yasutoshi

AU - Skine, Osamu

AU - Usuda, Yoshimaru

AU - Aoki, Nobuki

AU - Oyama, Kaoru

AU - Kanaki, Michiko

AU - Suzuki, Kunio

AU - Kitaura, Saburo

AU - Nanjo, Kunio

AU - Kato, Joichi

AU - Yamamoto, Toshiyuki

AU - Shiota, Kenzo

AU - Miki, Fumio

AU - Kono, Masakazu

AU - Okubo, Hiroshi

AU - Okamoto, Yuruko

AU - Ueda, Yoshiro

AU - Maehara, Keigo

AU - Tsujimoto, Takehiro

AU - Shimizu, Kenichi

AU - Maruyama, Hiroshi

AU - Soejima, Rinzo

AU - Tano, Yoshihiko

AU - Niki, Yoshihito

AU - Kurimura, Osamu

AU - Tamaki, Kazue

AU - Sasaki, Hideo

AU - Hara, Kohei

AU - Nakatomi, Masao

AU - Saito, Atsushi

AU - Nasu, Masaru

AU - Jzumikawa, Kinichi

AU - Iwasaki, Hiromaro

AU - Ikebe, Akira

AU - Tsutsumi, Tsuneo

AU - Oka, Rokushi

AU - Akaishi, Mitsunobu

AU - Tomonaga, Akimitsu

AU - Matsumoto, Keizo

AU - Shishido, Harumi

AU - Ide, Masatoshi

AU - Tokuomi, Haruhiko

AU - Shima, Kiyoshi

AU - Fukuda, Yasutsugu

AU - Hamada, Kazuhiro

AU - Tokunaga, Katsumasa

AU - Takaba, Yoshio

AU - Ishizaka, Kazuo

AU - Hiro, Yasumasa

AU - Tateishi, Noritaka

AU - Mishima, Isaoshi

AU - Kaku, Ryuji

AU - Higuchi, Sadanobu

AU - Nakahara, Norihiko

AU - Tomita, Tatsuo

AU - Takeuchi, Genshin

AU - Oba, Akio

AU - Nozute, Haruo

PY - 1980

Y1 - 1980

N2 - A comparative study of Cefuroxime with Cefazolin for bacterial pneumonia and chronic respiratory tract infections was carried out by the double blind method. Each one of the antibiotics was given in doses of 750 mg I. V. three times daily for seven to fourteen days. 1 Cases subject to analysis: Of 201 cases recruited in this trial, 149 (Cefuroxime 72, Cefazolin 77) were adopted by Committee in evaluation on clinical efficacy and 197 (Cefuroxime 96, Cefazolin 101) were adopted by Controller after judged by doctors in charge. The background characteristics of the patients in Cefuroxime and Cefazolin treated groups were almost the same. 2. Overall clinical efficacy judged by Committee: Cefuroxime was significantly superior to Cefazolin in judgement on the 7 th day of treatment in the “excellent” rate of total cases and of moderate cases, and in the efficacy of cases with infection due to gram positive cocci, etc. Cefuroxime showed also a tendency to be superior to Cefazolin in the “excellent” rate of patients with pneumonia, the efficacy rate of moderate cases and in the clinical efficacy in chronic respiratory tract infections, etc. 3. Overall clinical efficacy judged by doctors in charge: As for the overall clinical efficacy in total cases, there was no significant difference between Cefuroixme and Cefazolin in both judgements on the 7 th day of treatment and at the end of treatment. 4. Improvement of clinical findings: As for the degree of improvement in chest X-ray findings on the 14 th day of treatment compared with the initial ones, Cefuroxime was significantly superior to Cefazolin in cases adopted by Committee and showed a tendency to be superior to Cefazolin in cases adopted by Controller. Besides, Cefazolin showed a tendency to be better than Cefuroxime in property and volume (only cases adopted by Committee) of sputum in the judgement after three days treatment. 5. Bacteriological response classified by clinical isolates from sputum: Cefuroxime showed a tendency to eradicate Heamophilus at a higher rate than Cefazolin. 6. Side effects and abnormal laboratory findings due to the medication: As for the incidence of side effects including abnormal laboratory findings, there was no significant difference between Cefuroxime and Cefazolin in both judgements by Committee (186 cases) and those by doctors in charge (197 cases). 7. Clinical usefulness judged by doctors in charge: Cefuroxime showed a tendency to be superior to Cefazolin in usefulness rate (judged as useful or slightly useful). From the results obtained, it has been concluded that Cefuroxime is a useful antibiotic for treatment of bacterial pneumonia and chronic respiratory tract infections.

AB - A comparative study of Cefuroxime with Cefazolin for bacterial pneumonia and chronic respiratory tract infections was carried out by the double blind method. Each one of the antibiotics was given in doses of 750 mg I. V. three times daily for seven to fourteen days. 1 Cases subject to analysis: Of 201 cases recruited in this trial, 149 (Cefuroxime 72, Cefazolin 77) were adopted by Committee in evaluation on clinical efficacy and 197 (Cefuroxime 96, Cefazolin 101) were adopted by Controller after judged by doctors in charge. The background characteristics of the patients in Cefuroxime and Cefazolin treated groups were almost the same. 2. Overall clinical efficacy judged by Committee: Cefuroxime was significantly superior to Cefazolin in judgement on the 7 th day of treatment in the “excellent” rate of total cases and of moderate cases, and in the efficacy of cases with infection due to gram positive cocci, etc. Cefuroxime showed also a tendency to be superior to Cefazolin in the “excellent” rate of patients with pneumonia, the efficacy rate of moderate cases and in the clinical efficacy in chronic respiratory tract infections, etc. 3. Overall clinical efficacy judged by doctors in charge: As for the overall clinical efficacy in total cases, there was no significant difference between Cefuroixme and Cefazolin in both judgements on the 7 th day of treatment and at the end of treatment. 4. Improvement of clinical findings: As for the degree of improvement in chest X-ray findings on the 14 th day of treatment compared with the initial ones, Cefuroxime was significantly superior to Cefazolin in cases adopted by Committee and showed a tendency to be superior to Cefazolin in cases adopted by Controller. Besides, Cefazolin showed a tendency to be better than Cefuroxime in property and volume (only cases adopted by Committee) of sputum in the judgement after three days treatment. 5. Bacteriological response classified by clinical isolates from sputum: Cefuroxime showed a tendency to eradicate Heamophilus at a higher rate than Cefazolin. 6. Side effects and abnormal laboratory findings due to the medication: As for the incidence of side effects including abnormal laboratory findings, there was no significant difference between Cefuroxime and Cefazolin in both judgements by Committee (186 cases) and those by doctors in charge (197 cases). 7. Clinical usefulness judged by doctors in charge: Cefuroxime showed a tendency to be superior to Cefazolin in usefulness rate (judged as useful or slightly useful). From the results obtained, it has been concluded that Cefuroxime is a useful antibiotic for treatment of bacterial pneumonia and chronic respiratory tract infections.

UR - http://www.scopus.com/inward/record.url?scp=0019166660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019166660&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.28.687

DO - 10.11250/chemotherapy1953.28.687

M3 - Article

AN - SCOPUS:0019166660

VL - 28

SP - 687

EP - 714

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

SN - 0009-3165

IS - 5

ER -

A comparative study on the efficacy and the safety of cefuroxime and cefazolin in respiratory tract infections by doubie blind method

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this